The c‐Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK‐ERK and Akt‐independent mechanism
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cerebellar granule neurons undergo apoptosis when switched from a medium containing high potassium (HK) to one that has low potassium (LK). LK‐induced cell death is blocked by GW5074 {5‐Iodo‐3‐[(3,5‐dibromo‐4‐hydroxyphenyl) methylene]‐2‐indolinone}, a synthetic drug that inhibits c‐Raf activity in vitro. GW5074 has no direct effect on the activities of several apoptosis‐associated kinases when assayed in vitro. In contrast to its effect in vitro, treatment of neurons with GW5074 causes c‐Raf activation (when measured in vitro in the absence of the drug) and stimulates the Raf‐MEK‐ERK pathway. Treatment of neurons with GW5074 also leads to an increase in the activity of B‐Raf, which is not inhibited by GW5074 in vitro at concentrations at which the drug exerts its neuroprotective effect. PD98059 and U0126, two distinct inhibitors of MEK, block the activation of ERK by GW5074 but have no effect on its ability to prevent cell death. Overexpression of a dominant‐negative form of Akt does not reduce the efficacy of GW5074, demonstrating an Akt‐independent mechanism of action. Neuroprotection is inhibited by SN‐50, a specific inhibitor of nuclear factor‐kappa B (NF‐κB) and by the Ras inhibitor S‐trans, trans‐farnesylthiosalicylic acid (FTS) implicating NF‐κB and Ras in the neuroprotective signaling pathway activated by GW5074. In addition to preventing LK‐induced apoptosis, treatment with GW5074 protects against the neurotoxic effects of MPP+ and methylmercury in cerebellar granule neurons, and glutathione depletion‐induced oxidative stress in cortical neurons. Furthermore, GW5074 prevents neurodegeneration and improves behavioral outcome in an animal model of Huntington's disease. Given its neuroprotective effect on distinct types of cultured neurons, in response to different neurotoxic stimuli, and in an animal model of neurodegeneration, GW5074 could have therapeutic value against neurodegenerative pathologies in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of neuronal survival by the serine-threonine protein kinase Akt
Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.275.5300.661 · Cited by 2,436 · cited 4×
“One signaling pathway involved in the promotion of growth factor-mediated neuronal survival is the phosphatidylinositol 3-kinase (PI-3K)-Akt pathway (Datta et al. 1997; Dudek et al. 1997; Crowder and Freeman 1998).”
BackgroundInfluentialApoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605 · cited 1×
“Much of our knowledge of how neuronal apoptosis is regulated has come from in vitro paradigms using primary cultures of neurons, and several molecules involved in promoting neuronal apoptosis have been identified (reviewed in Deshmukh and Johnson 1997; D’Mello 1998; Chang et al. 2002; Mattson 2000).”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892
Self-citationDuncia, J. V., Santella, J. B., Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J.-H., Earl, R. A., Tabaka, A. C., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00522-8 · Cited by 401
Constitutive Nuclear Factor-κB Activity Is Required for Central Neuron Survival
Bhakar, A. L., Tannis, L.-L., Zeindler, C., Russo, M. P., Jobin, C., Park, D. S., MacPherson, S., & Barker, P. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08466.2002 · Cited by 310 · cited 2×
“…NF-jB protects neurons against a variety of apoptotic stimuli and reduced NF-jB activity has been associated with neurodegeneration both in vitro and in vivo survival (Yu et al. 1999; Glazner et al. 2000; Koulich et al. 2001; Yabe et al. 2001; Bhakar et al. 2002; reviewed in Mattson et al. 2000).”
BackgroundNeuronal apoptosis at the G1/S cell cycle checkpoint
Liu, D. X., & Greene, L. A. (2001) · Cell and Tissue Research · doi:10.1007/s004410100396 · Cited by 234
Coffey, E. T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., & Courtney, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04335.2002 · Cited by 184
Cited by
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Striatal microRNA controls cocaine intake through CREB signalling
Hollander, J. A., Im, H.-I., Amelio, A. L., Kocerha, J., Bali, P., Lu, Q., Willoughby, D., Wahlestedt, C., Conkright, M. D., & Kenny, P. J. (2010) · Nature · doi:10.1038/nature09202 · Cited by 388
Metadata
- Authors
- Chin, P. C., Liu, L., Morrison, B. E., Siddiq, A., Ratan, R. R., Bottiglieri, T., & D'Mello, S. R.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2004-06-18
- Volume
- 90
- Issue
- 3
- Pages
- 595-608
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1965133242
- Cited by
- 92
- References
- 7
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.